Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
About Us
BoD
Hervé Guérin
- Director
Hervé Guérin, a director since November 2006, has 30 years of pharmaceutical management experience. Since 2005, he has been a director of Xytis Pharmaceuticals. From 1999 to 2004, he was a director of Sanofi Synthelabo. From 1999 to 2001, he was the Vice Chairman and Chief Operating Officer of Sanofi Synthelabo. Prior to the merger of Sanofi and Synthelabo in 1999, Mr. Guérin had been the Chairman and Chief Executive Officer of Synthelabo since 1989. Mr. Guérin has also previously held positions as Regional President UK, Northern Europe, Middle East, Asia, Pacific & Africa for Rhône Poulenc and May & Baker. He was also Financial Vice President for Europe and Regional President for Canada, Latin America, Asia & Pacific for Revlon Healthcare. Mr. Guérin is a graduate from HEC and holds a MBA from Harvard Business School.